ProCE Banner Activity

CE / CME

Strategies for Mitigating Health Disparities in Patients With Anemia of CKD

Multimedia
In this microlearning module, an expert faculty discusses health disparities in patients with anemia of CKD and strategies to mitigate them.

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit™

Nurses: 0.25 Nursing contact hour

Released: January 20, 2023

Expiration: January 19, 2024

Share

Faculty

Ajay Singh

Ajay Singh, MBBS, FRCP, MBA

Senior Associate Dean for Postgraduate Education
Division of Nephrology
Brigham and Womens Hospital and Harvard Medical School
Nephrologist
Renal Division
Brigham and Womens Hospital
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

GlaxoSmithKline

Target Audience

This education is intended to reach nephrologists, hematologists, primary care (internal medicine and family medicine) hospitalists, cardiologists, endocrinologists, nurses, physician assistants/physician associates, and/or allied healthcare providers who use multichannel platforms and reach a national or regional audience.

Learning Objectives

  • Describe mitigation strategies that can help reduce health disparities in patients of color with anemia of CKD

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Ajay Singh, MBBS, FRCP, MBA

Senior Associate Dean for Postgraduate Education
Division of Nephrology
Brigham and Womens Hospital and Harvard Medical School
Nephrologist
Renal Division
Brigham and Womens Hospital
Boston, Massachusetts

Ajay Singh, MBBS, FRCP, MBA: consultant/advisor/speaker: Bayer, GlaxoSmithKline, Zydus.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until January 19, 2024. PAs should only claim commensurate with the extent of their participation.

Disclosure of Unlabeled Use

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 20, 2023, through January 19, 2024:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100.00% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this program is to improve the knowledge and competence of learners with regard to increased screening of patients with CKD for comorbid anemia and safely treating patients with supplemental iron/ESA or emerging novel therapies that increase endogenous EPO production.